Figure 6.

Mutational landscape in 14 CMML patients who transformed to AML (n = 13) or to myelofibrosis (n = 1). Each row corresponds to one gene. Each blue square corresponds to one patient at CMML diagnosis, and each orange square corresponds to one patient at transformation. White squares indicate unanalyzed genes. Gray squares indicate unmutated genes. Red squares indicate that the original mutation was retained at transformation. Light green squares indicate mutations acquired at transformation. Yellow squares indicate mutations not retained at transformation. Dark green squares indicate a mutation present at transformation but not analyzed at diagnosis. Ten patients (1, 2, 4, 5, 6, 7, 8, 10, 12, and 13) had not previously received disease-modifying treatment and they maintained most of the same mutations with an increased VAF. Patients 4, 6, 7, 8, 10, and 12 had acquired new mutations at the time of AML transformation. Three patients (3, 9, and 11) had received disease-modifying treatment prior to AML transformation.